Andrew Ch Chen1, Jon Morgenstern2, Christine M Davis3, Alexis N Kuerbis4, Jonathan Covault, Henry R Kranzler. 1. Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, USA. 2. Research Foundation for Mental Hygiene, Inc., New York State Psychiatric Institute, New York, USA. 3. Department of Psychiatry, University of Connecticut Health Center, Farmington, CT, USA. 4. Treatment Research Center, Department of Psychiatry, Perelman School of Medicine of the University of Pennsylvania and VISN4 MIRECC, Philadelphia VAMC Philadelphia, USA.
Abstract
BACKGROUND: It is well known that naltrexone, an FDA-approved medication for treatment of alcohol dependence, is effective for only a subset of individuals. Recent studies have examined the utility of a functional A118G single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1) as a predictor of naltrexone treatment response. Although the findings to date have generally been consistent with a moderating effect of the SNP, further evaluation of this hypothesis is warranted. OBJECTIVE: To evaluate whether problem drinkers with one or two copies of the 118G allele respond better tonaltrexone treatment. The treatment goal in this cohort of high functioning men who have sex with men (MSM) was to reduce heavy drinking, rather than to promote abstinence. METHOD: 112 subjects of European ancestry from a randomized clinical trial ofnaltrexone and behavioral therapy for problem drinking MSM were included in the analysis. Subjects were treated for 12 weeks with 100 mg/day of oral naltrexone hydrochloride. All participants received medical management with a modified version of the Brief Behavioral Compliance Enhancement Treatment (BBCET), alone or in combination with Modified Behavioral Self-control Therapy (MBSCT). RESULTS:Naltrexone-treated subjects with one or two 118G alleles had a significantly greater percentage of non-hazardous drinking (NoH) (p < 0.01) than those treated with placebo or A118 homozygotes in either medication group. CONCLUSIONS: These results are consistent with a modest moderating effect of the OPRM1 118G allele on the reduction of heavy drinking by naltrexone treatment.
RCT Entities:
BACKGROUND: It is well known that naltrexone, an FDA-approved medication for treatment of alcohol dependence, is effective for only a subset of individuals. Recent studies have examined the utility of a functional A118G single nucleotide polymorphism (SNP) of the mu-opioid receptor gene (OPRM1) as a predictor of naltrexone treatment response. Although the findings to date have generally been consistent with a moderating effect of the SNP, further evaluation of this hypothesis is warranted. OBJECTIVE: To evaluate whether problem drinkers with one or two copies of the 118G allele respond better to naltrexone treatment. The treatment goal in this cohort of high functioning men who have sex with men (MSM) was to reduce heavy drinking, rather than to promote abstinence. METHOD: 112 subjects of European ancestry from a randomized clinical trial of naltrexone and behavioral therapy for problem drinking MSM were included in the analysis. Subjects were treated for 12 weeks with 100 mg/day of oral naltrexone hydrochloride. All participants received medical management with a modified version of the Brief Behavioral Compliance Enhancement Treatment (BBCET), alone or in combination with Modified Behavioral Self-control Therapy (MBSCT). RESULTS:Naltrexone-treated subjects with one or two 118G alleles had a significantly greater percentage of non-hazardous drinking (NoH) (p < 0.01) than those treated with placebo or A118 homozygotes in either medication group. CONCLUSIONS: These results are consistent with a modest moderating effect of the OPRM1 118G allele on the reduction of heavy drinking by naltrexone treatment.
Authors: Helen M Pettinati; Charles P O'Brien; Amanda R Rabinowitz; Shoshana P Wortman; David W Oslin; Kyle M Kampman; Charles A Dackis Journal: J Clin Psychopharmacol Date: 2006-12 Impact factor: 3.153
Authors: Jon Morgenstern; Alexis N Kuerbis; Andrew C Chen; Christopher W Kahler; Donald A Bux; Henry R Kranzler Journal: J Consult Clin Psychol Date: 2012-05-21
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman Journal: Arch Gen Psychiatry Date: 2008-02
Authors: Andrew C H Chen; Christine M Davis; Christopher W Kahler; Alexis N Kuerbis; Jonathan Covault; Henry R Kranzler; Jon Morgenstern Journal: Alcohol Clin Exp Res Date: 2014-07-28 Impact factor: 3.455